MGRX MANGOCEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, MANGOCEUTICALS INC reported revenue of $68.8K (down 59.1% from a year earlier), net income of −$1.31M and diluted EPS of −$0.09; over the last four quarters revenue was $315K and net income −$15.1M; for the fiscal year ended December 2025 revenue was $456K, down 26.0% on the year before.
MGRX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $456K, gross profit $250K, operating income −$18.0M, net income −$20.6M (margin -4526.8%), EPS −$2.17
- Fiscal year ended Dec 2024: revenue $616K, gross profit $380K, operating income −$7.97M, net income −$8.71M (margin -1413.6%), EPS −$4.80
- Fiscal year ended Dec 2023: revenue $731K, gross profit $432K, operating income −$9.22M, net income −$9.21M (margin -1259.4%), EPS −$8.58
- Fiscal year ended Dec 2022: revenue $8.94K, gross profit $4.85K, operating income −$1.99M, net income −$2.00M (margin -22352.1%), EPS −$0.19
MGRX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $68.8K (down 59.1% year over year), net income −$1.31M, EPS −$0.09
- Quarter ended Mar 31, 2026: revenue $67.9K (down 37.9% year over year), net income −$3.40M, EPS −$0.22
- Quarter ended Dec 31, 2025 (from the annual report): revenue $94.4K (down 10.3% year over year), net income −$2.77M, EPS $0.21
- Quarter ended Sep 30, 2025: revenue $84.2K (down 36.8% year over year), net income −$7.62M, EPS −$0.69
- Quarter ended Jun 30, 2025: revenue $168K (up 3.0% year over year), net income −$5.42M, EPS −$0.57
- Quarter ended Mar 31, 2025: revenue $109K (down 48.9% year over year), net income −$4.84M, EPS −$1.12
- Quarter ended Dec 31, 2024 (from the annual report): revenue $105K (down 56.9% year over year), net income −$1.95M, EPS −$0.79
- Quarter ended Sep 30, 2024: revenue $133K (down 45.6% year over year), net income −$2.00M, EPS −$1.14
- Quarter ended Jun 30, 2024: revenue $163K (up 15.5% year over year), net income −$2.39M, EPS −$1.37
- Quarter ended Mar 31, 2024: revenue $214K (up 112.6% year over year), net income −$2.37M, EPS −$1.50
- Quarter ended Dec 31, 2023 (from the annual report): revenue $244K, net income −$2.57M, EPS −$6.51
- Quarter ended Sep 30, 2023: revenue $245K, net income −$1.80M, EPS −$1.70
- Quarter ended Jun 30, 2023: revenue $141K, net income −$2.28M, EPS −$0.14
- Quarter ended Mar 31, 2023: revenue $101K, net income −$2.56M, EPS −$0.23
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$673K, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$995K, EPS −$0.10
- Quarter ended Jun 30, 2022: revenue n/a, net income −$310K, EPS −$0.04
- Quarter ended Mar 31, 2022: revenue n/a, net income −$19.6K, EPS n/a
MGRX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$5.85M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$4.86M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$7.00M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$1.35M, share buybacks n/a
MGRX balance sheet
- Jun 30, 2026: cash $229K, total assets $14.2M, total liabilities $1.65M, shareholders' equity $12.5M
- Mar 31, 2026: cash $175K, total assets $14.4M, total liabilities $975K, shareholders' equity $13.5M
- Dec 31, 2025: cash $1.49M, total assets $16.1M, total liabilities $891K, shareholders' equity $15.2M
- Sep 30, 2025: cash $481K, total assets $16.5M, total liabilities $804K, shareholders' equity $15.7M
- Jun 30, 2025: cash $101K, total assets $20.8M, total liabilities $1.60M, shareholders' equity $19.2M
- Mar 31, 2025: cash $76.5K, total assets $21.8M, total liabilities $1.50M, shareholders' equity $20.3M
- Dec 31, 2024: cash $58.7K, total assets $15.4M, total liabilities $1.43M, shareholders' equity $13.9M
- Sep 30, 2024: cash $73.9K, total assets $14.8M, total liabilities $1.40M, shareholders' equity $13.4M
What is MGRX's revenue?
MANGOCEUTICALS INC reported $315K of revenue over its last four quarters, through June 30, 2026.
Is MGRX profitable?
No. MANGOCEUTICALS INC lost $15.1M over the last four quarters.
What is MGRX's EPS?
Diluted earnings per share over the last four quarters were −$0.79; −$0.09 in the latest quarter.